Novo Nordisk's stock appears to have formed a long-term bottom as its turnaround gains momentum, with losses in market share to Eli Lilly stabilizing. Trading at just over 15 times forward earnings, the stock is valued at about half of Eli Lilly's multiple, reflecting reduced downside risk amid improved guidance and strong profitability. Despite pricing pressures and lower gross margins, Novo Nordisk's weight loss products remain highly profitable, boosted by the recent success of the Wegovy pill. The stock's next target is forecasted at $60, with potential regulatory approval of CagriSema in late 2026 as a key catalyst. While competition with Eli Lilly continues, Novo Nordisk now has more room to outperform and surprise the market positively.
Deutsche Bank downgraded Novo Nordisk shares from 'hold' to 'sell', cutting the target price by 9% due to concerns over midterm growth and pipeline setbacks. The downgrade follows a mixed Q2 update and highlights worries about limited Medicare prescr...
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
